Rizvi et al. explored an autocrine Hippo/FGFR signaling in cholangiocarcinoma and determined that FGFR1, −2, and −4 expression is in part driven by YAP/TBX5 complex, but this is not true for FGFR3 because it doesn’t have a TBX5 binding sequence. This evidence concerns the gene TBX5 and cholangiocarcinoma.